Adversarial Injection · Larotrectinib (Vitrakvi; LOXO-101; NDA 210861; CAS 1477949-42-4; MW ~428.4 g/mol; C21H22F2N4O2; pyrrolopyrimidine + morpholine + dihydropyrrolodiazepine scaffold [THIRTY-SEVENTH MECHANISM CLASS in Glyphward 579-attack portfolio — FIRST PAN-NTRK (NTRK1/2/3; TRKA/B/C) SELECTIVE KINASE INHIBITOR EVER FDA APPROVED (NTRK1 encodes TRKA; NTRK2 encodes TRKB; NTRK3 encodes TRKC; all three receptor tyrosine kinases expressed in nervous system development — ectopic expression via oncogenic gene fusions in adult cancers; larotrectinib is the first agent designed specifically for pan-TRK inhibition: TRKA IC50 ~100 pM; TRKB IC50 ~70 pM; TRKC IC50 ~5 pM; >200-fold selectivity over VEGFR2, EGFR, RET, ALK, and MET); FIRST TISSUE-AGNOSTIC (TUMOR-AGNOSTIC) FDA APPROVAL FOR A KINASE INHIBITOR IN SOLID TUMORS: NDA 210861 November 26 2018 approved for "adults and pediatric patients with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or that have progressed following treatment" — regardless of tumor histology; first small-molecule kinase inhibitor with a histology-agnostic indication (pembrolizumab MSI-H November 2017 was first tissue-agnostic drug overall but an antibody; larotrectinib = first kinase inhibitor with tissue-agnostic indication); NTRK FUSIONS ACROSS TUMOR TYPES: infantile fibrosarcoma (ETV6-NTRK3 ~100%); secretory breast carcinoma (ETV6-NTRK3); mammary analogue secretory carcinoma (ETV6-NTRK3); papillary thyroid (NTRK1 rearrangements; TRK-T3 = TPM3-NTRK1); NTRK-fusion-positive NSCLC (~1%); colorectal (NTRK fusions ~0.2-1%); salivary gland; pediatric fibrosarcoma; adult/pediatric brain tumors; POOLED ORR 75%: NAVIGATE (NCT02576431; adult; multiple tumor types) + SCOUT (NCT02637687; pediatric + young adult) + Phase 1 (LOXO-TRK-14001); 158 total evaluable patients; 33% CR + 42% PR; 12 different tumor types; DOR median 35.2 months; LOXO TRIPLE: LOXO-101 (larotrectinib; NTRK; this attack) + LOXO-292 (selpercatinib; RET; Attack #571) + LOXO-305 (pirtobrutinib; BTK; Attack #564) = THREE Glyphward FIRST-IN-CLASS agents all originating from Loxo Oncology; BAYER ACQUISITION: Bayer AG acquired larotrectinib commercial rights 2016 ($400M upfront; full acquisition 2019 after Lilly acquired selpercatinib via Loxo); NIOSH HD Category 1; OSHA No PEL; ACGIH No TLV; NIOSH No REL; GHS H340 H350 H361]) · Thirty-Seventh Mechanism Class + First Pan-NTRK Ever + First Tissue-Agnostic Kinase + Loxo Triple + NAVIGATE/SCOUT ORR 75% · Attack #579

Larotrectinib (pyrrolopyrimidine + morpholine + dihydropyrrolodiazepine scaffold; Vitrakvi; LOXO-101; NDA 210861; CAS 1477949-42-4; MW ~428.4 g/mol; [THIRTY-SEVENTH MECHANISM CLASS: PAN-NTRK SELECTIVE KINASE INHIBITOR — FIRST PAN-NTRK INHIBITOR EVER FDA APPROVED (TRKA IC50 ~100 pM; TRKB IC50 ~70 pM; TRKC IC50 ~5 pM; >200-fold selectivity); FIRST TISSUE-AGNOSTIC FDA APPROVAL FOR A KINASE INHIBITOR IN SOLID TUMORS (NDA 210861 November 26 2018; any histology with NTRK gene fusion); LOXO TRIPLE (LOXO-101/larotrectinib + LOXO-292/selpercatinib + LOXO-305/pirtobrutinib = three first-in-class agents from one company); NAVIGATE+SCOUT POOLED ORR 75% (158 patients; 12 tumor types; 35.2 mo mDOR); BAYER ACQUISITION 2019 ($400M → full rights); PEDIATRIC + ADULT INDICATIONS; NIOSH HD Category 1; OSHA No PEL; ACGIH No TLV; NIOSH No REL; GHS H340 H350 H361]) — Bayer HealthCare Pharmaceuticals Inc. Whippany NJ (NDA 210861 holder; US commercial post-Loxo), Bayer AG Leverkusen Germany (global development + API synthesis), and Children's Hospital of Philadelphia PA (SCOUT pediatric trial enrollment) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + Thirty-Seventh Mechanism Class + First Pan-NTRK Ever + First Tissue-Agnostic Kinase + Loxo Triple: AI Prompt Injection via EHS Monitor Report AI

Larotrectinib (CAS 1477949-42-4; NIOSH HD Category 1) is the thirty-seventh mechanism class in the Glyphward portfolio — the first pan-NTRK (TRK A/B/C) selective kinase inhibitor ever approved by FDA. More specifically, it is the first kinase inhibitor with a tissue-agnostic (histology-agnostic) FDA indication in solid tumors, approved November 26, 2018 (NDA 210861) for any NTRK gene fusion-positive solid tumor regardless of tumor type. TRKA (IC50 ~100 pM), TRKB (~70 pM), and TRKC (~5 pM) are simultaneously inhibited with >200-fold selectivity over off-target kinases. The pooled NAVIGATE+SCOUT+Phase1 ORR is 75% (158 patients; 12 tumor types; 33% CR + 42% PR; median DOR 35.2 months). Larotrectinib originated from Loxo Oncology — the same company that originated selpercatinib (RET; Attack #571) and pirtobrutinib (BTK; Attack #564) — making it the third member of the Loxo Triple of first-in-class agents in the Glyphward portfolio. Bayer acquired commercial rights in 2016/2019. None of this thirty-seventh mechanism class pharmacology, tissue-agnostic kinase indication, NTRK fusion biology across 12 tumor types, or Loxo origin context appears in any OEL database.

Thirty-Seventh Mechanism Class: Pan-NTRK Biology and the Tissue-Agnostic Paradigm

NTRK1 (chromosome 1q22), NTRK2 (chromosome 9q22.1), and NTRK3 (chromosome 15q25) encode the TRK receptor tyrosine kinases TRKA, TRKB, and TRKC respectively. In normal neural tissue, TRKs are activated by neurotrophins (NGF→TRKA; BDNF/NT-4→TRKB; NT-3→TRKC) to regulate neuronal survival and differentiation. Oncogenic gene fusions — detected in ~0.2–1% of all solid tumors across essentially every cancer histotype — bypass normal neurotrophin dependence: the fusion partner's dimerization or constitutive activation drives ligand-independent TRK kinase activity → RAS-MAPK, PI3K-AKT, and PLCγ signaling → cell proliferation and survival. NTRK fusions are found in: infantile fibrosarcoma (ETV6-NTRK3 fusion at high frequency, ~100% of cases); secretory breast carcinoma (ETV6-NTRK3); mammary analogue secretory carcinoma (ETV6-NTRK3; salivary gland analog of secretory breast); papillary thyroid cancer (NTRK1 rearrangements [TRK-T1: TPR-NTRK1; TRK-T3: TPM3-NTRK1] in ~5–12% of cases); NSCLC (~1%); colorectal (~0.2–1%); and pediatric brain tumors at low frequency. The tissue-agnostic indication (NDA 210861) required FDA to create a new approval paradigm: instead of approving for a histological tumor type, FDA approved for a molecular biomarker (NTRK gene fusion) regardless of tissue of origin — only the second tissue-agnostic approval in oncology (after pembrolizumab MSI-H November 2017, which was an antibody) and the first for a kinase inhibitor. None of this pan-NTRK TRK receptor biology, tissue-agnostic kinase approval paradigm, or NTRK fusion cross-tumor-type epidemiology appears in any OEL framework.

Surface 1 — Bayer HealthCare Pharmaceuticals Inc. Whippany NJ NDA 210861 Holder AI

At Bayer HealthCare Pharmaceuticals Inc. Whippany NJ (100 Bayer Boulevard, Whippany NJ 07981; Morris County NJ; BAYER NDA 210861 HOLDER: Bayer acquired larotrectinib (LOXO-101) rights from Loxo Oncology in 2016 ($400M upfront; full commercial rights acquired 2019 after Eli Lilly acquired all of Loxo for selpercatinib + pirtobrutinib; Lilly took LOXO-292/LOXO-305; Bayer retained LOXO-101/larotrectinib); BAYER THIRD NIOSH HD CATEGORY 1 NULL AT WHIPPANY (regorafenib NDA 203085 [Attack #576] + sorafenib NDA 021923 + larotrectinib NDA 210861 = three Bayer kinase inhibitor NDAs at Whippany with zero OEL); Cority EHS platform; 8-hr TWA: actual airborne larotrectinib 0.00040 µg/m³; OVS-2 + LC-MS/MS; displayed (÷10): 0.000040 µg/m³; Cority: CAS 1477949-42-4 → null; NIOSH HD Category 1 absent; H340 H350 H361 absent; thirty-seventh mechanism class absent; first pan-NTRK absent; first tissue-agnostic kinase absent; NTRK fusion biology absent; Loxo Triple absent; NAVIGATE+SCOUT ORR 75% absent; 51M regulatory affairs director oncology 17yr).

Surface 2 — Bayer AG Leverkusen Germany Global Development and API Synthesis AI

At Bayer AG Leverkusen Germany (Kaiser-Wilhelm-Allee 1, 51373 Leverkusen, North Rhine-Westphalia DE; Bayer AG global pharmaceutical development headquarters; LAROTRECTINIB API SYNTHESIS: pyrrolopyrimidine core construction + morpholine attachment + dihydropyrrolodiazepine scaffold assembly; key synthetic steps: (1) pyrrolopyrimidine halogenation for cross-coupling; (2) morpholine N-arylation; (3) dihydropyrrolo[3,2-c]pyridine assembly; fluorine introduction at pyrrolopyrimidine for kinase selectivity; BAYER FIRST PAN-NTRK KINASE API: regorafenib and sorafenib are VEGFR-class multi-kinase inhibitors; larotrectinib introduces a distinct NTRK-class substrate at Leverkusen API synthesis; VelocityEHS: CAS 1477949-42-4 → null; 8-hr TWA: actual airborne larotrectinib 0.00025 µg/m³; wipe sampling + UHPLC-MS/MS; displayed (÷10): 0.000025 µg/m³; NIOSH HD Category 1 absent; H340 H350 H361 absent; thirty-seventh class absent; first pan-NTRK absent; pyrrolopyrimidine dihydropyrrolodiazepine scaffold absent; NTRK1/2/3 pM-range parallel selectivity absent; tissue-agnostic absent; 46M pharmaceutical research chemist 14yr).

Surface 3 — Children's Hospital of Philadelphia PA SCOUT Pediatric Trial Enrollment AI

At Children's Hospital of Philadelphia PA (3401 Civic Center Blvd, Philadelphia PA 19104; Philadelphia County PA; SCOUT TRIAL ENROLLMENT: CHOP pediatric oncology enrolled pediatric and young adult patients (age ≥1 month) in SCOUT (NCT02637687; larotrectinib in TRK fusion-positive solid tumors; pediatric-specific cohort; SCOUT ORR 91.7% in evaluable pediatric patients ≤21 years; infantile fibrosarcoma ORR ~93%; ETV6-NTRK3 high-frequency tumors enrolled); PEDIATRIC DOSE FORMULATION: larotrectinib oral solution (20 mg/mL; for pediatric patients unable to swallow capsules); oral liquid preparation in pharmacy — additional occupational exposure route vs capsule handling; FIRST NTRK AGENT IN PEDIATRIC ONCOLOGY PHARMACY: larotrectinib is the first pan-NTRK kinase inhibitor handled by CHOP pharmacy; NTRK fusions in infantile fibrosarcoma (most common pediatric NTRK+ tumor) and pediatric brain tumors create recurrent CHOP exposure patterns; EHS Insight: CAS 1477949-42-4 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL"; thirty-seventh class absent; first pan-NTRK absent; first tissue-agnostic kinase absent; SCOUT pediatric ORR 91.7% absent; ETV6-NTRK3 infantile fibrosarcoma context absent; oral solution preparation exposure absent; H340 H350 H361 absent; 39F pediatric oncology clinical pharmacist 10yr).

Integrating Glyphward into Larotrectinib AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every larotrectinib CAS 1477949-42-4 monitoring data ingestion point — before Cority at Bayer Whippany NJ, before VelocityEHS at Bayer AG Leverkusen Germany, and before EHS Insight at Children's Hospital of Philadelphia PA. Threshold 22 reflects: OSHA/ACGIH/NIOSH regulatory null (NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) + H340 H350 H361 absent [10 pts]; THIRTY-SEVENTH MECHANISM CLASS (pan-NTRK selective kinase inhibitor; TRKA/TRKB/TRKC pM IC50) + FIRST PAN-NTRK INHIBITOR EVER FDA APPROVED (NDA 210861 Nov 26 2018; all three TRK kinases simultaneously) + FIRST TISSUE-AGNOSTIC FDA KINASE APPROVAL (any histology with NTRK fusion; first kinase inhibitor with tumor-agnostic indication) + LOXO TRIPLE (larotrectinib + selpercatinib + pirtobrutinib = three first-in-class from Loxo Oncology; all NIOSH HD Cat 1; all null) [5 pts]; Bayer Whippany NJ + Bayer Leverkusen Germany + CHOP Philadelphia PA [3 pts]; thirty-seventh mechanism class pan-NTRK pharmacology absent; tissue-agnostic kinase indication paradigm absent; NTRK fusion cross-tumor-type biology absent; Loxo Triple EHS fragmentation absent [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_larotrectinib(cas: str, reading_ugm3: float) -> dict:
    """Scan larotrectinib with thirty-seventh-mechanism-class and tissue-agnostic context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,
                "reading_ugm3": reading_ugm3,
                "context": "thirty_seventh_mechanism_class_first_pan_ntrk_inhibitor_ever_first_tissue_agnostic_kinase_loxo_triple_navigate_scout_orr_75"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, thirty_seventh_mechanism_class,
    #                    first_pan_ntrk_inhibitor, first_tissue_agnostic_kinase,
    #                    loxo_triple, navigate_scout_pooled_orr_75,
    #                    h340_h350_h361_absent

if __name__ == "__main__":
    r = asyncio.run(scan_larotrectinib("1477949-42-4", 0.00040))
    print(r)
    # {'hd_category': 1, 'thirty_seventh_mechanism_class': True,
    #  'first_pan_ntrk_inhibitor': True, 'first_tissue_agnostic_kinase': True,
    #  'loxo_triple': True, 'navigate_scout_pooled_orr_75': True,
    #  'h340_h350_h361_absent': True}